• Swedish Orphan Biovitrum flagged new clinical data for Gamifant in primary HLH for presentation at HS2026 in Rotterdam.
• Results will be presented in the future, during the Sept. 26-29 meeting, with poster sessions scheduled for Sept. 29.
• The program highlights pooled evidence on survival outcomes around transplant, positioning Gamifant as a bridge to curative HSCT.
• Additional analyses point to rapid, durable responses across patient subgroups, including those with prior treatment or CNS involvement.
• Post-authorization study data in treatment-experienced Chinese patients will add real-world safety and efficacy context relevant to uptake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Swedish Orphan Biovitrum AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.